Low Serum miR-19a Expression as a Novel Poor Prognostic Indicator in Multiple Myeloma

International Journal of Cancer - United States
doi 10.1002/ijc.29199
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Prognostic Value of CD56 Expression in Multiple Myeloma

Research in Oncology
2020English

TAZ Expression as a Prognostic Indicator in Colorectal Cancer

PLoS ONE
Multidisciplinary
2013English

Serum miR-26a as a Diagnostic and Prognostic Biomarker in Cholangiocarcinoma

Oncotarget
Oncology
2015English

Low Expression of Aldo–keto Reductase 1B10 Is a Novel Independent Prognostic Indicator for Nasopharyngeal Carcinoma

Cell and Bioscience
BiochemistryGeneticsMolecular Biology
2016English

Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and in Vivo Evidence

Clinical Cancer Research
Cancer ResearchOncology
2012English

Serum Bone Sialoprotein as a Marker of Tumour Burden and Neoplastic Bone Involvement and as a Prognostic Factor in Multiple Myeloma

British Journal of Cancer
Cancer ResearchOncology
2001English

Evaluation of Serum Β 2-Microglobulin as a Prognostic Indicator in Myelomatosis

British Journal of Cancer
Cancer ResearchOncology
1983English

High Expression of UBE2T Predicts Poor Prognosis and Survival in Multiple Myeloma

Cancer Gene Therapy
Cancer ResearchMolecular MedicineMolecular Biology
2019English

MicroRNA-19a Acts as a Prognostic Marker and Promotes Prostate Cancer Progression via Inhibiting VPS37A Expression

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy